alendronate has been researched along with Kahler Disease in 17 studies
alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Multiple myeloma is a malignancy of plasma cells with osteolytic bone destruction." | 6.71 | Biphasic anti-osteoclastic action of intravenous alendronate therapy in multiple myeloma bone disease. ( Hamano, T; Kitano, M; Ogata, A; Sano, H; Sekiguchi, M, 2005) |
| "Multiple myeloma is a malignancy of plasma cells with osteolytic bone destruction." | 2.71 | Biphasic anti-osteoclastic action of intravenous alendronate therapy in multiple myeloma bone disease. ( Hamano, T; Kitano, M; Ogata, A; Sano, H; Sekiguchi, M, 2005) |
| "Oral etidronate has been found to be ineffective in patients with multiple myeloma and prostate carcinoma bone metastases." | 2.41 | Oral bisphosphonates: A review of clinical use in patients with bone metastases. ( Berenson, J; Hortobagyi, G; Lipton, A; Major, PP, 2000) |
| " Twelve patients who presented with exposed bone associated with bisphosphonates were reviewed to determine the type, dosage and duration of their bisphosphonate therapy, presenting findings, comorbidities and the event that incited the bone exposure." | 1.34 | Bisphosphonate-associated osteonecrosis of the jaw in patients with multiple myeloma and breast cancer. ( Alati, C; Allegra, A; Alonci, A; Cicciù, M; De Ponte, FS; Musolino, C; Nastro, E; Oteri, G; Quartarone, E, 2007) |
| "Sixty-two (52." | 1.33 | Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. ( Broumand, V; Fortin, M; Marx, RE; Sawatari, Y, 2005) |
| "Here we report 29 cases of bone necrosis of the jaws in patients treated with pamidronate (Aredia), zoledronate (Zometa) and alendronate: 15 underwent surgical procedures and 14 occurred spontaneously." | 1.33 | Bone necrosis of the jaws associated with bisphosphonate treatment: a report of twenty-nine cases. ( Bonaninil, M; Corcione, L; Corradi, D; D'Aleo, P; Ferrari, S; Guidotti, R; Manfredi, M; Meleti, M; Merigo, E; Poli, T; Ripasarti, A; Sesenna, E; Vescovi, P; Zanzucchi, E, 2006) |
| "Pamidronate-treated bone marrow (BM) cultures of 24 patients with MM showed significantly reduced plasma cell survival compared with untreated cultures, especially in cultures in which activation of BM-gamma delta T cells was evident (14 of 24 patients with MM)." | 1.31 | Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. ( Bauer, E; Feurle, J; Kunzmann, V; Tony, HP; Weissinger, F; Wilhelm, M, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.88) | 18.2507 |
| 2000's | 10 (58.82) | 29.6817 |
| 2010's | 6 (35.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Borm, JM | 1 |
| Moser, S | 1 |
| Locher, M | 1 |
| Damerau, G | 1 |
| Stadlinger, B | 1 |
| Grätz, KW | 1 |
| Jacobsen, C | 1 |
| Swami, A | 1 |
| Reagan, MR | 1 |
| Basto, P | 1 |
| Mishima, Y | 1 |
| Kamaly, N | 1 |
| Glavey, S | 1 |
| Zhang, S | 1 |
| Moschetta, M | 1 |
| Seevaratnam, D | 1 |
| Zhang, Y | 1 |
| Liu, J | 1 |
| Memarzadeh, M | 1 |
| Wu, J | 1 |
| Manier, S | 1 |
| Shi, J | 1 |
| Bertrand, N | 1 |
| Lu, ZN | 1 |
| Nagano, K | 1 |
| Baron, R | 1 |
| Sacco, A | 1 |
| Roccaro, AM | 1 |
| Farokhzad, OC | 1 |
| Ghobrial, IM | 1 |
| Chang, Q | 1 |
| Geng, R | 1 |
| Wang, S | 1 |
| Qu, D | 1 |
| Kong, X | 1 |
| Fedele, S | 1 |
| Porter, SR | 1 |
| D'Aiuto, F | 1 |
| Aljohani, S | 1 |
| Vescovi, P | 2 |
| Manfredi, M | 2 |
| Arduino, PG | 1 |
| Broccoletti, R | 1 |
| Musciotto, A | 1 |
| Di Fede, O | 1 |
| Lazarovici, TS | 1 |
| Campisi, G | 1 |
| Yarom, N | 1 |
| Martins, MA | 1 |
| Martins, MD | 1 |
| Lascala, CA | 1 |
| Curi, MM | 1 |
| Migliorati, CA | 1 |
| Tenis, CA | 1 |
| Marques, MM | 1 |
| Freiberger, JJ | 1 |
| Padilla-Burgos, R | 1 |
| McGraw, T | 1 |
| Suliman, HB | 1 |
| Kraft, KH | 1 |
| Stolp, BW | 1 |
| Moon, RE | 1 |
| Piantadosi, CA | 1 |
| Ogata, A | 2 |
| Kitano, M | 2 |
| Hashimoto, N | 1 |
| Iwasaki, T | 1 |
| Hamano, T | 2 |
| Kakishita, E | 1 |
| Salomo, M | 1 |
| Jurlander, J | 1 |
| Nielsen, LB | 1 |
| Gimsing, P | 1 |
| Sekiguchi, M | 1 |
| Sano, H | 1 |
| Carter, G | 1 |
| Goss, AN | 1 |
| Doecke, C | 1 |
| Marx, RE | 1 |
| Sawatari, Y | 1 |
| Fortin, M | 1 |
| Broumand, V | 1 |
| Nastro, E | 1 |
| Musolino, C | 1 |
| Allegra, A | 1 |
| Oteri, G | 1 |
| Cicciù, M | 1 |
| Alonci, A | 1 |
| Quartarone, E | 1 |
| Alati, C | 1 |
| De Ponte, FS | 1 |
| Merigo, E | 1 |
| Meleti, M | 1 |
| Guidotti, R | 1 |
| Ripasarti, A | 1 |
| Zanzucchi, E | 1 |
| D'Aleo, P | 1 |
| Corradi, D | 1 |
| Corcione, L | 1 |
| Sesenna, E | 1 |
| Ferrari, S | 1 |
| Poli, T | 1 |
| Bonaninil, M | 1 |
| Body, JJ | 1 |
| Coleman, RE | 1 |
| Piccart, M | 1 |
| Major, PP | 1 |
| Lipton, A | 1 |
| Berenson, J | 1 |
| Hortobagyi, G | 1 |
| Kunzmann, V | 1 |
| Bauer, E | 1 |
| Feurle, J | 1 |
| Weissinger, F | 1 |
| Tony, HP | 1 |
| Wilhelm, M | 1 |
| Das, H | 1 |
| Wang, L | 1 |
| Kamath, A | 1 |
| Bukowski, JF | 1 |
3 reviews available for alendronate and Kahler Disease
| Article | Year |
|---|---|
[Risk assessment in patients undergoing osseous antiresorptive therapy in dentistry. An update].
Topics: Aged; Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Age | 2013 |
Use of bisphosphonates in cancer patients.
Topics: Alendronate; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Clodronic Acid; Diphosphonates; Etid | 1996 |
Oral bisphosphonates: A review of clinical use in patients with bone metastases.
Topics: Alendronate; Biological Availability; Bone Density; Bone Neoplasms; Bone Resorption; Breast Neoplasm | 2000 |
2 trials available for alendronate and Kahler Disease
| Article | Year |
|---|---|
What is the role of hyperbaric oxygen in the management of bisphosphonate-related osteonecrosis of the jaw: a randomized controlled trial of hyperbaric oxygen as an adjunct to surgery and antibiotics.
Topics: Aged; Alendronate; Anti-Bacterial Agents; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone D | 2012 |
Biphasic anti-osteoclastic action of intravenous alendronate therapy in multiple myeloma bone disease.
Topics: Adult; Aged; Alendronate; Anesthetics, Intravenous; beta 2-Microglobulin; Biomarkers, Tumor; Bone Di | 2005 |
12 other studies available for alendronate and Kahler Disease
| Article | Year |
|---|---|
Engineered nanomedicine for myeloma and bone microenvironment targeting.
Topics: Alendronate; Animals; Antineoplastic Agents; Bone Neoplasms; Boronic Acids; Bortezomib; Cell Line, T | 2014 |
DOPA-based paclitaxel-loaded liposomes with modifications of transferrin and alendronate for bone and myeloma targeting.
Topics: Alendronate; Animals; Antineoplastic Agents; Apoptosis; Bone and Bones; Cell Line, Tumor; Chemistry, | 2016 |
Nonexposed variant of bisphosphonate-associated osteonecrosis of the jaw: a case series.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Breast Neoplasms; Dip | 2010 |
Association of laser phototherapy with PRP improves healing of bisphosphonate-related osteonecrosis of the jaws in cancer patients: a preliminary study.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bon | 2012 |
Chemotherapy did not enhance the anti-osteolytic effects of bisphosphonate in multiple myeloma bone disease.
Topics: Adult; Alendronate; Biomarkers; Bone Diseases; Drug Therapy, Combination; Female; Humans; Multiple M | 2002 |
How myeloma cells escape bisphosphonate-mediated killing: development of specific resistance with preserved sensitivity to conventional chemotherapeutics.
Topics: Alendronate; Alkyl and Aryl Transferases; Apoptosis; Blotting, Western; Diphosphonates; Drug Resista | 2003 |
Bisphosphonates and avascular necrosis of the jaw: a possible association.
Topics: Aged; Aged, 80 and over; Alendronate; Anti-Inflammatory Agents; Diphosphonates; Female; Follow-Up St | 2005 |
Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment.
Topics: Abscess; Alendronate; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Breas | 2005 |
Bisphosphonate-associated osteonecrosis of the jaw in patients with multiple myeloma and breast cancer.
Topics: Alendronate; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Fem | 2007 |
Bone necrosis of the jaws associated with bisphosphonate treatment: a report of twenty-nine cases.
Topics: Aged; Aged, 80 and over; Alendronate; Anti-Bacterial Agents; Antifungal Agents; Bone Density Conserv | 2006 |
Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma.
Topics: Alendronate; Antigens, CD; Antigens, Differentiation, T-Lymphocyte; Bone Marrow Cells; Cell Division | 2000 |
Vgamma2Vdelta2 T-cell receptor-mediated recognition of aminobisphosphonates.
Topics: Alendronate; Antigens; Cell Line, Transformed; Cytotoxicity, Immunologic; Diphosphonates; Etidronic | 2001 |